Beta Bionics Q3 2026 slides: record revenue, strategic wins offset loss

Beta Bionics released its Q3 2026 financial results on October 27, 2026, reporting record revenue and strategic achievements despite posting a larger-than-expected loss. The diabetes device manufacturer disclosed $35.5 million in net sales, accompanied by FDA approval of its Mint patch pump and advancements across ongoing pipeline programs.

Nonetheless, operational expenses escalated faster than revenue growth, driven by investments in commercialization and product development. Shares experienced a 13% drop in after-hours trading, settling at $18.61 following a trading day where they opened at $21.39, up 4.29%. The company's adjusted earnings per share (EPS) of -$0.52 exceeded market expectations, which stood at -$0.32 per share.